4-Week TB pill could replace months of treatment for millions at risk
NCT ID NCT06568484
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a 4-week course of the drug bedaquiline can prevent tuberculosis (TB) as well as standard longer treatments. It involves 2,530 people living with HIV and close contacts of TB patients. The goal is to find a safer, easier-to-complete prevention option.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBERCULOSIS, LATENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
HNSEB (Hospital Nacional Sergio E. Bernales)
NOT_YET_RECRUITINGLima, Peru
-
Joint Clinical Research Centre
RECRUITINGKampala, Uganda
-
Kilimanjaro Clinical Research Institute
RECRUITINGMoshi, Tanzania
-
MU-JHU Care Ltd.
RECRUITINGKampala, Uganda
-
Makerere Lung Institute
NOT_YET_RECRUITINGKampala, Uganda
-
SES Policlinico
NOT_YET_RECRUITINGLima, Peru